Press Releases Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
74.57 ^USD	-1.17%		+14.39%	+18.74%

May. 14	Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
May. 08	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update	May. 08	GL
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	Mar. 04	GL
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 27	GL
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	Feb. 15	GL
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	Feb. 02	AQ
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	Feb. 02	GL
Vaxcyte to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	Feb. 01	GL
Vaxcyte Announces Pricing of $750 Million Public Offering	Jan. 30	GL
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants	Jan. 30	GL
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older	Jan. 29	GL
Vaxcyte Appoints Whitney Jones as Chief People Officer	Jan. 16	GL
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise	Jan. 04	GL
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate	Dec. 04	GL
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate	Dec. 04	AQ
Vaxcyte Appoints Jacks Lee to Board of Directors	Nov. 28	GL
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	Nov. 27	GL
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	Nov. 27	AQ
Chronic Periodontitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 14	AQ
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults	Nov. 09	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Press Releases

Filters